Phaseline

Targets › FBIAB

FBIAB: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Dec 2027.

Open in Phaseline: the race on FBIAB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Asan Medical CenterPretomanid
Mycobacterial bioenergetics inhibitor (prodrug activated by Mycobacterium tuberculosis)
FBIABPhase 4Multidrug- and Rifampicin-resistant TuberculosisDec 2027

Conditions

Multidrug- and Rifampicin-resistant Tuberculosis (1)

Modalities

small molecule (1)

Companies

Asan Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.